Try our mobile app

Switch to company model in classical logic    *

General information

Country: BRITAIN

Sector: Biotechnology

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1...
Website: centessa.com




Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -6.5% (LTM)

Entry Point: Share price is 675.2% higher than minimum and 21.5% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $3.9 mln (-0.155% of cap.)

Key Financials (Download financials)

Ticker: CNTA
Share price, USD:  (-0.2%)23.49
year average price 18.82  


year start price 19.03 2025-02-08

min close price 10.71 2025-04-08

max close price 29.91 2025-12-05

current price 23.49 2026-02-07
Common stocks: 94 040 998

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 2 209
Net Debt ($m): -470
EV (Enterprise Value): 1 739
Price to Book: 7.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-01fool.com

This Fund Locked In Gains With a $14.5 Million Biotech Exit Amid a Staggering Stock Rally

2026-01-14globenewswire.com

Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

2025-11-29fool.com

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company

2025-11-11globenewswire.com

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

2025-06-04zacks.com

Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet

2025-01-08globenewswire.com

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

2024-09-28marketbeat.com

Wake Up to This Biotech Stock That Still Has Big Potential Upside

2024-09-26globenewswire.com

Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

2024-09-12globenewswire.com

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

2024-09-11globenewswire.com

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-12 2024-11-12 2024-10-18 2024-05-13 2023-11-13 2023-08-14 2023-05-12 2022-11-10 2022-08-10
acceptedDate 2025-11-05 07:31:36 2025-08-12 07:13:54 2025-03-24 07:31:13 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00 2022-03-30 16:09:59 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
revenue 0 0 0 0 0 0 7M 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 236 264 239 862 0 236 618 237 762 0 0 0 0 0 0
grossProfit 0 0 0 0 -236 264 -239 862 7M -236 618 -237 762 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 42M 43M 150M 34M 33M 23M 124M 28M 34M 33M 155M 37M 54M 96M 9M
generalAndAdministrativeExpenses 12M 12M 51M 13M 11M 13M 54M 12M 13M 16M 55M 12M 15M 43M 1M
sellingAndMarketingExpenses 0 0 0 0 0 -247 537 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 12M 12M 51M 13M 11M 13M 54M 12M 13M 16M 55M 12M 15M 43M 1M
otherExpenses 0 0 0 0 0 -2M 0 -2M -2M -1M 2M 0 0 236M 0
operatingExpenses 54M 55M 201M 46M 44M 36M 178M 40M 47M 49M 212M 49M 68M 375M 10M
costAndExpenses 54M 55M 201M 46M 44M 36M 178M 40M 47M 49M 212M 49M 68M 375M 10M
interestIncome 4M 4M 14M 3M 3M 3M 10M 3M 2M 3M 244 000 0 0 0 0
interestExpense 3M 3M 10M 3M 3M 3M 10M 3M 2M 2M 7M 2M 2M 3M 378 000
depreciationAndAmortization 237 000 226 000 942 000 7M 236 000 239 862 810 000 238 000 237 000 1M 131 000 -3M 32 000 34 000 0
ebitda -52M -46M -222M -39M -40M -36M -165M -39M -46M -48M -210M -52M -63M -139M -10M
ebitdaratio 0 0 0 0 0 0 0 0 0 0
operatingIncome -54M -55M -201M -46M -44M -36M -171M -40M -47M -49M -212M -49M -68M -375M -10M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -935 000 5M -32M 4M 869 000 -1M -5M -2M -2M -1M -5M -5M 4M -7M -223 000
incomeBeforeTax -55M -50M -233M -42M -43M -38M -176M -41M -49M -50M -217M -54M -65M -382M -11M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0 0
incomeTaxExpense 166 000 778 000 3M 608 000 705 000 480 725 -25M -3M -24M 677 000 -747 000 -141 000 -22 000 114 000 0
netIncome -55M -50M -236M -43M -44M -38M -151M -39M -25M -51M -216M -54M -65M -382M -11M
netIncomeRatio 0 0 0 0 0 0 0 0 0 0
eps -0.41 -0.38 -2.06 -0.37 -0.4 -0.38 -1.57 -0.4 -0.26 -0.53 -2.31 -0.57 -0.69 -4.24 -0.078
epsdiluted -0.41 -0.38 -0.37 -0.4 -0.38 -0.4 -0.26 -0.53 -0.57 -0.69
weightedAverageShsOut 134M 134M 114M 116M 109M 100M 96M 97M 95M 95M 93M 94M 94M 90M 71M
weightedAverageShsOutDil 134M 134M 114M 116M 109M 100M 96M 97M 95M 95M 93M 94M 94M 90M 71M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-28 2023-03-30 2022-03-30 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 4M 570 000 -7M -3M -378 000
ebit -223M -166M -210M -139M -10M
nonOperatingIncomeExcludingInterest 22M -5M -3M -236M -155 000
netIncomeFromContinuingOperations -236M -151M -216M -382M -11M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 -1 0
bottomLineNetIncome -236M -151M -216M -381M -11M
epsDiluted -2.06 -1.57 -2.31 -4.24 -0.078

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-12 2024-11-12 2024-10-18 2024-05-13 2023-11-13 2023-08-14 2023-05-12 2022-11-10 2022-08-10
acceptedDate 2025-11-05 07:31:36 2025-08-12 07:13:54 2025-03-24 07:31:13 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00 2022-05-02 16:30:25 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
cashAndCashEquivalents 51M 44M 383M 395M 127M 118M 128M 171M 145M 260M 394M 445M 484M 595M 7M
shortTermInvestments 195M 206M 99M 123M 167M 112M 129M 110M 158M 86M 0 0 0 0 0
cashAndShortTermInvestments 246M 251M 482M 518M 295M 230M 257M 281M 304M 346M 394M 445M 484M 595M 7M
netReceivables 52M 44M 45M 40M 47M 37M 39M 30M 28M 23M 27M 22M 22M 17M 0
inventory 0 0 0 0 0 1 0 18M 15M 12M 0 0 0 0 0
otherCurrentAssets 9M 6M 2M 10M 14M 17M 2M 3M 4M 3M 3M 1M 14M 993 000 4M
totalCurrentAssets 308M 300M 536M 568M 356M 284M 315M 332M 350M 384M 438M 477M 519M 629M 11M
propertyPlantEquipmentNet 11M 11M 12M 12M 12M 13M 13M 13M 13M 13M 1M 552 000 905 000 162 000 0
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 103M 153M 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 25M 25M 27M 27M 29M 29M 30M 30M 27M 0 4M 0 0 0 0
otherNonCurrentAssets 2M 2M 2M 2M 2M 2M 3M 2M 2M 6M 2M 2M 648 000 699 000 552 000
totalNonCurrentAssets 141M 192M 40M 41M 43M 44M 45M 45M 43M 20M 7M 2M 2M 861 000 552 000
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 448M 492M 577M 610M 399M 328M 360M 377M 393M 404M 444M 479M 521M 630M 12M
accountPayables 9M 6M 7M 7M 5M 7M 12M 11M 11M 14M 14M 11M 8M 8M 1M
shortTermDebt 684 000 656 000 0 577 000 552 000 528 000 0 482 000 460 000 398 000 0 0 0 0 6M
taxPayables 55 000 257 000 835 000 0 0 0 112 000 0 0 2M 2M 0 0 769 000 0
deferredRevenue 0 0 0 0 0 0 0 23M 22M 0 0 0 0 0 0
otherCurrentLiabilities 20M 23M 10M 18M 21M 19M 839 000 159 000 507 000 15M 8M 27M 25M 5M 922 000
totalCurrentLiabilities 29M 30M 58M 26M 27M 27M 39M 35M 34M 30M 38M 38M 34M 25M 9M
longTermDebt 118M 117M 109M 84M 85M 77M 76M 83M 82M 81M 70M 68M 67M 76M 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 29 000 29 000 29 000 29 000 29 000 9M 29 000 0 0 0 0 57M 43 000 38M 0
totalNonCurrentLiabilities 118M 118M 117M 84M 85M 86M 85M 83M 82M 81M 70M 68M 67M 113M 0
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 8M 9M 8M 577 000 9M 9M 9M 10M 10M 10M 0 0 0 0 0
totalLiabilities 147M 147M 175M 111M 112M 113M 124M 118M 116M 111M 108M 106M 101M 138M 9M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 364 000 363 000 359 000 357 000 309 000 277 000 273 000 271 000 266 000 266 000 265 000 263 000 263 000 252 000 26M
retainedEarnings -1 120M -1 065M -989M -877M -835M -791M -753M -716M -677M -653M -602M -559M -505M -386M -24M
accumulatedOtherComprehensiveIncomeLoss 3M 2M 4M 2M 2M 2M 1M 779 000 946 000 -599 000 -1M -2M -1M 688 000 572 000
othertotalStockholdersEquity 1 419M 1 408M 1 374M 1 120M 1 004M 974M 953M 946M 933M 926M
totalStockholdersEquity 302M 345M 402M 499M 287M 215M 236M 259M 277M 293M 336M 373M 420M 492M 3M
totalEquity 302M 345M 402M 499M 287M 215M 236M 259M 277M 293M 336M 373M 420M 492M 3M
totalLiabilitiesAndStockholdersEquity 448M 492M 610M 399M 328M 377M 393M 404M 479M 521M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 448M 492M 577M 610M 399M 328M 360M 377M 393M 404M 444M 479M 521M 630M 12M
totalInvestments 298M 360M 99M 123M 167M 112M 129M 110M 158M 86M 0 0 0 0 0
totalDebt 118M 118M 117M 85M 86M 86M 85M 84M 83M 81M 70M 68M 67M 76M 6M
netDebt 67M 74M -266M -310M -42M -32M -43M -88M -62M -179M -324M -377M -417M -519M -2M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-28 2023-03-30 2022-05-02 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 45M 0 27M 17M 0
otherReceivables 0 39M 0 0 0
prepaids 7M 18M 14M 16M 9000
totalPayables 8M 12M 15M 9M 1M
otherPayables 835 000 112 000 2M 769 000 0
accruedExpenses 40M 27M 15M 11M 1M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 8M 9M 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 386M 987M 939M 876M 825 000
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2021-12-31 2020-12-31
symbol CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA CNTA
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-05 2025-08-12 2024-11-12 2024-10-18 2024-05-13 2023-11-13 2023-08-14 2023-05-12 2022-11-10 2022-08-10
acceptedDate 2025-11-05 07:31:36 2025-08-12 07:13:54 2025-03-24 07:31:13 2024-11-12 07:16:41 2024-10-18 16:01:01 2024-05-13 16:32:10 2024-03-28 16:44:50 2023-11-13 16:22:34 2023-08-14 07:18:13 2023-05-12 07:14:36 2023-03-30 07:44:44 2022-11-10 07:09:10 2022-08-10 06:58:00 2022-05-02 16:30:25 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 Q2 FY FY
netIncome -55M -50M -236M -43M -44M -38M -151M -39M -25M -51M -216M -54M -65M -382M -11M
depreciationAndAmortization 237 000 226 000 942 000 236 000 236 000 239 862 810 000 238 000 237 000 89 000 131 000 35 000 32 000 33 995 0
deferredIncomeTax 255 000 1M 3M 1M 567 000 433 752 -27M -3M -24M 0 -3M 0 0 0 0
stockBasedCompensation 7M 8M 34M 8M 9M 8M 29M 8M 7M 7M 25M 7M 6M 0 336 000
changeInWorkingCapital -11M 19M 22M 12M -6M -9M -19M -4M -6M -5M -3M 7M 6M -5M -489 000
accountsReceivables -10M 11M -7M 10M 0 1M 0 -2M -6M 0 -12M 0 0 -7M -1M
inventory 0 0 0 0 0 0 0 2M 6M 0 0 0 0 0 0
accountsPayables 3M 177 000 -5M 2M -2M -4M -3M 83 000 -2M -2M 6M 3M 2M 0 -49 000
otherWorkingCapital -5M 8M 33M 255 000 -4M -6M -16M -5M -4M 2M 3M 4M 0 1M 1M
otherNonCashItems 157 000 137 000 34M -570 000 -290 051 13M 6M 795 000 3M 975 000 -4M 665 000 -7M 251M 186 000
netCashProvidedByOperatingActivities -58M -22M -142M -21M -41M -37M -160M -37M -44M -48M -201M -39M -60M -136M -11M
investmentsInPropertyPlantAndEquipment -234 000 -126 000 -34 000 -34 001 1.551 0 -169 000 -43 000 -10000 -88 000 -1M -16 000 -229 000 -185 977 0
acquisitionsNet 0 0 0 0 0 0 0 -87M 0 0 0 0 0 63M 0
purchasesOfInvestments -46M -83M -141M 147M -121M -20M -265M -37M -71M -86M 0 0 0 0 0
salesMaturitiesOfInvestments 108M 43M 172M 45M 65M 37M 138M 87M 0 0 0 0 0 0 0
otherInvestingActivites 0 0 -147M -52 905 17M 86M 0 0 0 0
netCashUsedForInvestingActivites 62M -40M 45M -55M 17M 49M -71M -86M -16 000 -229 000
debtRepayment 0 0 0 0 0 0 0 0 0 0
commonStockIssued 0 2M 243M 107M 10M 15M 12 075 0 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 -11 998 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 3M -152 095 3M -2M 10M -65 089 -75 0 224 000 70 000
netCashUsedProvidedByFinancingActivities 3M 2M 246M 105M 10M 15M 12 000 0 224 000 70 000
effectOfForexChangesOnCash -501 000 -113 000 1M -2M -120 000 219 000 615 000 220 000 381 000 518 000 -418 000 -438 000 -268 000 3M -75 000
netChangeInCash 7M -61M 255M 268M 9M -10M -266M 26M -115M -134M -201M -39M -60M 590M -9M
cashAtEndOfPeriod 51M 44M 383M 395M 127M 118M 128M 171M 145M 260M 394M 445M 484M 595M 7M
cashAtBeginningOfPeriod 44M 105M 128M 127M 118M 128M 394M 145M 260M 394M 595M 484M 544M 5M 17M
operatingCashFlow -58M -22M -142M -21M -41M -37M -160M -37M -44M -48M -201M -39M -60M -136M -11M
capitalExpenditure -234 000 -126 000 -34 000 -34 001 1.551 0 -169 000 -43 000 -10000 -88 000 -1M -16 000 -229 000 -185 982 0
freeCashFlow -59M -23M -142M -21M -41M -37M -161M -37M -44M -48M -202M -39M -60M -136M -11M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link
filingDate 2025-03-24 2024-03-28 2023-03-30 2022-05-02 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 206 000 0 0
netCashProvidedByInvestingActivities 31M -127M -931 000 63M 0
netDebtIssuance -762 000 0 0 74M 1M
longTermNetDebtIssuance -762 000 0 0 74M 1M
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 360M 21M 0 586M 0
netCommonStockIssuance 360M 21M 0 586M 0
commonStockIssuance 360M 21M 0 586M 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 6M 310 000 457 000 0 1000
netCashProvidedByFinancingActivities 365M 21M 457 000 660M 1M
incomeTaxesPaid 82 000 3M 1M 0 0
interestPaid 10M 10M 7M 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2025-11-24 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-24 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-24 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-13 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-13 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-13 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-13 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-13 12:24 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 10
2025-11-05 12:31 ET
Centessa Pharmaceuticals plc reported for 2025 q3
SEC form 8
2025-11-05 12:23 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-05 12:23 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 8
2025-11-05 12:23 ET
Centessa Pharmaceuticals plc published news for 2025 q3
SEC form 10
2025-08-12 11:13 ET
Centessa Pharmaceuticals plc reported for 2025 q2
SEC form 8
2025-08-12 11:07 ET
Centessa Pharmaceuticals plc published news for 2025 q2
SEC form 8
2025-08-12 11:07 ET
Centessa Pharmaceuticals plc published news for 2025 q2
SEC form 8
2025-06-17 21:02 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 8
2025-06-17 21:02 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 10
2025-05-14 11:18 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Centessa Pharmaceuticals plc published news for 2025 q1
SEC form 10
2025-03-24 11:31 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 10
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 8
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 8
2025-03-24 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q4
SEC form 10
2024-11-12 07:16 ET
Centessa Pharmaceuticals plc reported for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 8
2024-11-12 07:08 ET
Centessa Pharmaceuticals plc published news for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2024 q3
SEC form 10
2024-08-13 07:27 ET
Centessa Pharmaceuticals plc reported for 2024 q2
SEC form 8
2024-08-13 07:15 ET
Centessa Pharmaceuticals plc published news for 2024 q2
SEC form 8
2024-08-13 07:15 ET
Centessa Pharmaceuticals plc published news for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Centessa Pharmaceuticals plc reported for 2024 q2
SEC form 10
2024-05-13 16:32 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 8
2024-05-13 16:23 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 8
2024-05-13 16:23 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 10
2024-05-13 00:00 ET
Centessa Pharmaceuticals plc published news for 2024 q1
SEC form 10
2024-03-28 16:44 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 8
2024-03-28 16:35 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 8
2024-03-28 16:35 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Centessa Pharmaceuticals plc published news for 2023 q4
SEC form 10
2023-11-13 16:22 ET
Centessa Pharmaceuticals plc reported for 2023 q3
SEC form 8
2023-11-13 16:17 ET
Centessa Pharmaceuticals plc published news for 2023 q3
SEC form 10
2023-11-13 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q3
SEC form 10
2023-08-14 07:18 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 6
2023-08-14 07:06 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 8
2023-08-14 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q2
SEC form 6
2023-07-10 17:00 ET
Centessa Pharmaceuticals plc published news for 2023 q2
SEC form 6
2023-06-23 17:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-06-22 16:05 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-05-15 08:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 10
2023-05-12 07:14 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 6
2023-05-12 07:04 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Centessa Pharmaceuticals plc reported for 2023 q1
SEC form 6
2023-04-04 17:05 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:04 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:04 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:03 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:02 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 6
2023-04-04 17:01 ET
Centessa Pharmaceuticals plc published news for 2023 q1
SEC form 10
2023-03-30 07:44 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 6
2023-03-30 07:19 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 10
2023-03-30 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q4
SEC form 6
2023-01-27 17:14 ET
Centessa Pharmaceuticals plc published news for 2022 q4
SEC form 6
2023-01-26 11:28 ET
Centessa Pharmaceuticals plc published news for 2022 q4
SEC form 6
2022-12-23 16:27 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-12-12 06:37 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-12-05 16:39 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 10
2022-11-10 07:09 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 6
2022-11-10 07:04 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q3
SEC form 6
2022-10-14 07:00 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-10-06 17:06 ET
Centessa Pharmaceuticals plc published news for 2022 q3
SEC form 6
2022-09-12 07:16 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 10
2022-08-10 06:58 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 6
2022-08-10 06:45 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q2
SEC form 6
2022-07-08 16:32 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-07-06 18:00 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-07-01 08:45 ET
Centessa Pharmaceuticals plc published news for 2022 q2
SEC form 6
2022-06-30 16:34 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-06-02 06:33 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-05-23 08:00 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-05-16 07:41 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 6
2022-05-16 07:14 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q1
SEC form 8
2022-05-16 00:00 ET
Centessa Pharmaceuticals plc reported for 2022 q1
SEC form 6
2022-05-02 16:30 ET
Centessa Pharmaceuticals plc published news for 2022 q1
SEC form 10
2022-03-30 16:09 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-30 16:06 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-15 17:30 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-03-14 07:38 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-24 07:37 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-16 16:15 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2022-02-11 21:59 ET
Centessa Pharmaceuticals plc published news for 2021 q4
SEC form 6
2021-12-14 07:58 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 10
2021-11-15 07:13 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-11-15 07:11 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Centessa Pharmaceuticals plc published news for
SEC form 8
2021-11-15 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-11-01 07:38 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-10-08 18:00 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-10-04 08:07 ET
Centessa Pharmaceuticals plc published news for 2021 q3
SEC form 6
2021-09-09 07:34 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 10
2021-08-16 07:07 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-08-16 07:05 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 8
2021-08-16 00:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-07-06 19:00 ET
Centessa Pharmaceuticals plc published news for 2021 q2
SEC form 6
2021-05-27 20:34 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:32 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:32 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:31 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:31 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:30 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:26 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:26 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:25 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:25 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:24 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:23 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:22 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1
SEC form 6
2021-05-27 20:20 ET
Centessa Pharmaceuticals plc published news for 2021 q1